nodes	percent_of_prediction	percent_of_DWPC	metapath
Pindolol—Ocular discomfort—Methotrexate—lymphatic system cancer	0.0232	0.0232	CcSEcCtD
Pindolol—Transaminases increased—Carmustine—lymphatic system cancer	0.0187	0.0187	CcSEcCtD
Pindolol—Depression—Mechlorethamine—lymphatic system cancer	0.0153	0.0153	CcSEcCtD
Pindolol—Sleep disorder—Fludarabine—lymphatic system cancer	0.0149	0.0149	CcSEcCtD
Pindolol—Aggression—Bleomycin—lymphatic system cancer	0.0149	0.0149	CcSEcCtD
Pindolol—Cardiac failure congestive—Fludarabine—lymphatic system cancer	0.0142	0.0142	CcSEcCtD
Pindolol—Visual disturbance—Fludarabine—lymphatic system cancer	0.0136	0.0136	CcSEcCtD
Pindolol—Cardiac failure—Fludarabine—lymphatic system cancer	0.0132	0.0132	CcSEcCtD
Pindolol—Tinnitus—Mechlorethamine—lymphatic system cancer	0.0129	0.0129	CcSEcCtD
Pindolol—Wheezing—Bleomycin—lymphatic system cancer	0.0127	0.0127	CcSEcCtD
Pindolol—Bronchospasm—Teniposide—lymphatic system cancer	0.0125	0.0125	CcSEcCtD
Pindolol—Sweating—Teniposide—lymphatic system cancer	0.0109	0.0109	CcSEcCtD
Pindolol—Vertigo—Mechlorethamine—lymphatic system cancer	0.0108	0.0108	CcSEcCtD
Pindolol—Visual impairment—Fludarabine—lymphatic system cancer	0.00862	0.00862	CcSEcCtD
Pindolol—Cardiac failure congestive—Mitoxantrone—lymphatic system cancer	0.00848	0.00848	CcSEcCtD
Pindolol—Psoriasis—Methotrexate—lymphatic system cancer	0.0084	0.0084	CcSEcCtD
Pindolol—Bronchospasm—Bleomycin—lymphatic system cancer	0.00806	0.00806	CcSEcCtD
Pindolol—Cardiac failure—Mitoxantrone—lymphatic system cancer	0.00788	0.00788	CcSEcCtD
Pindolol—Chest pain—Teniposide—lymphatic system cancer	0.00754	0.00754	CcSEcCtD
Pindolol—Confusional state—Teniposide—lymphatic system cancer	0.00729	0.00729	CcSEcCtD
Pindolol—Oedema—Teniposide—lymphatic system cancer	0.00723	0.00723	CcSEcCtD
Pindolol—Tachycardia—Teniposide—lymphatic system cancer	0.00705	0.00705	CcSEcCtD
Pindolol—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00699	0.00699	CcSEcCtD
Pindolol—Pruritus—Mechlorethamine—lymphatic system cancer	0.00694	0.00694	CcSEcCtD
Pindolol—Hypotension—Teniposide—lymphatic system cancer	0.00675	0.00675	CcSEcCtD
Pindolol—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00671	0.00671	CcSEcCtD
Pindolol—Myalgia—Fludarabine—lymphatic system cancer	0.00663	0.00663	CcSEcCtD
Pindolol—Arthralgia—Fludarabine—lymphatic system cancer	0.00663	0.00663	CcSEcCtD
Pindolol—Dyspnoea—Teniposide—lymphatic system cancer	0.00644	0.00644	CcSEcCtD
Pindolol—Confusional state—Fludarabine—lymphatic system cancer	0.0064	0.0064	CcSEcCtD
Pindolol—Depression—Carmustine—lymphatic system cancer	0.00636	0.00636	CcSEcCtD
Pindolol—Oedema—Fludarabine—lymphatic system cancer	0.00635	0.00635	CcSEcCtD
Pindolol—Erectile dysfunction—Vincristine—lymphatic system cancer	0.00628	0.00628	CcSEcCtD
Pindolol—Vomiting—Mechlorethamine—lymphatic system cancer	0.00623	0.00623	CcSEcCtD
Pindolol—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00623	0.00623	CcSEcCtD
Pindolol—Rash—Mechlorethamine—lymphatic system cancer	0.00618	0.00618	CcSEcCtD
Pindolol—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00618	0.00618	CcSEcCtD
Pindolol—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00614	0.00614	CcSEcCtD
Pindolol—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.00612	0.00612	CcSEcCtD
Pindolol—Depression—Vincristine—lymphatic system cancer	0.00607	0.00607	CcSEcCtD
Pindolol—Weight increased—Mitoxantrone—lymphatic system cancer	0.00605	0.00605	CcSEcCtD
Pindolol—Feeling abnormal—Teniposide—lymphatic system cancer	0.00596	0.00596	CcSEcCtD
Pindolol—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00593	0.00593	CcSEcCtD
Pindolol—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00591	0.00591	CcSEcCtD
Pindolol—Sweating—Vincristine—lymphatic system cancer	0.00583	0.00583	CcSEcCtD
Pindolol—Nausea—Mechlorethamine—lymphatic system cancer	0.00582	0.00582	CcSEcCtD
Pindolol—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00579	0.00579	CcSEcCtD
Pindolol—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.00576	0.00576	CcSEcCtD
Pindolol—Abdominal pain—Teniposide—lymphatic system cancer	0.00571	0.00571	CcSEcCtD
Pindolol—Paraesthesia—Fludarabine—lymphatic system cancer	0.0057	0.0057	CcSEcCtD
Pindolol—Hallucination—Carmustine—lymphatic system cancer	0.00569	0.00569	CcSEcCtD
Pindolol—Sweating—Mitoxantrone—lymphatic system cancer	0.00568	0.00568	CcSEcCtD
Pindolol—Dyspnoea—Fludarabine—lymphatic system cancer	0.00566	0.00566	CcSEcCtD
Pindolol—Dyspepsia—Fludarabine—lymphatic system cancer	0.00559	0.00559	CcSEcCtD
Pindolol—Visual impairment—Carmustine—lymphatic system cancer	0.00551	0.00551	CcSEcCtD
Pindolol—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00548	0.00548	CcSEcCtD
Pindolol—Fatigue—Fludarabine—lymphatic system cancer	0.00548	0.00548	CcSEcCtD
Pindolol—Hallucination—Vincristine—lymphatic system cancer	0.00543	0.00543	CcSEcCtD
Pindolol—Constipation—Fludarabine—lymphatic system cancer	0.00543	0.00543	CcSEcCtD
Pindolol—Pain—Fludarabine—lymphatic system cancer	0.00543	0.00543	CcSEcCtD
Pindolol—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00542	0.00542	CcSEcCtD
Pindolol—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00523	0.00523	CcSEcCtD
Pindolol—Asthenia—Teniposide—lymphatic system cancer	0.00519	0.00519	CcSEcCtD
Pindolol—Pruritus—Teniposide—lymphatic system cancer	0.00511	0.00511	CcSEcCtD
Pindolol—Cardiac disorder—Vincristine—lymphatic system cancer	0.00507	0.00507	CcSEcCtD
Pindolol—Mental disorder—Carmustine—lymphatic system cancer	0.00501	0.00501	CcSEcCtD
Pindolol—Angiopathy—Vincristine—lymphatic system cancer	0.00496	0.00496	CcSEcCtD
Pindolol—Diarrhoea—Teniposide—lymphatic system cancer	0.00494	0.00494	CcSEcCtD
Pindolol—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00492	0.00492	CcSEcCtD
Pindolol—Chest pain—Bleomycin—lymphatic system cancer	0.00486	0.00486	CcSEcCtD
Pindolol—Myalgia—Bleomycin—lymphatic system cancer	0.00486	0.00486	CcSEcCtD
Pindolol—Mental disorder—Vincristine—lymphatic system cancer	0.00479	0.00479	CcSEcCtD
Pindolol—Confusional state—Bleomycin—lymphatic system cancer	0.0047	0.0047	CcSEcCtD
Pindolol—Tremor—Carmustine—lymphatic system cancer	0.00467	0.00467	CcSEcCtD
Pindolol—Oedema—Bleomycin—lymphatic system cancer	0.00466	0.00466	CcSEcCtD
Pindolol—Vomiting—Teniposide—lymphatic system cancer	0.00459	0.00459	CcSEcCtD
Pindolol—Asthenia—Fludarabine—lymphatic system cancer	0.00456	0.00456	CcSEcCtD
Pindolol—Rash—Teniposide—lymphatic system cancer	0.00456	0.00456	CcSEcCtD
Pindolol—Dermatitis—Teniposide—lymphatic system cancer	0.00455	0.00455	CcSEcCtD
Pindolol—Headache—Teniposide—lymphatic system cancer	0.00453	0.00453	CcSEcCtD
Pindolol—Pruritus—Fludarabine—lymphatic system cancer	0.00449	0.00449	CcSEcCtD
Pindolol—Hypotension—Bleomycin—lymphatic system cancer	0.00435	0.00435	CcSEcCtD
Pindolol—Diarrhoea—Fludarabine—lymphatic system cancer	0.00435	0.00435	CcSEcCtD
Pindolol—Nausea—Teniposide—lymphatic system cancer	0.00429	0.00429	CcSEcCtD
Pindolol—Vertigo—Vincristine—lymphatic system cancer	0.00427	0.00427	CcSEcCtD
Pindolol—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00424	0.00424	CcSEcCtD
Pindolol—Chest pain—Carmustine—lymphatic system cancer	0.00424	0.00424	CcSEcCtD
Pindolol—Myalgia—Carmustine—lymphatic system cancer	0.00424	0.00424	CcSEcCtD
Pindolol—Anxiety—Carmustine—lymphatic system cancer	0.00423	0.00423	CcSEcCtD
Pindolol—Paraesthesia—Bleomycin—lymphatic system cancer	0.00418	0.00418	CcSEcCtD
Pindolol—Dyspnoea—Bleomycin—lymphatic system cancer	0.00415	0.00415	CcSEcCtD
Pindolol—Confusional state—Carmustine—lymphatic system cancer	0.0041	0.0041	CcSEcCtD
Pindolol—Oedema—Carmustine—lymphatic system cancer	0.00407	0.00407	CcSEcCtD
Pindolol—Myalgia—Vincristine—lymphatic system cancer	0.00405	0.00405	CcSEcCtD
Pindolol—Visual disturbance—Methotrexate—lymphatic system cancer	0.00404	0.00404	CcSEcCtD
Pindolol—Vomiting—Fludarabine—lymphatic system cancer	0.00404	0.00404	CcSEcCtD
Pindolol—Rash—Fludarabine—lymphatic system cancer	0.004	0.004	CcSEcCtD
Pindolol—Dermatitis—Fludarabine—lymphatic system cancer	0.004	0.004	CcSEcCtD
Pindolol—Pain—Bleomycin—lymphatic system cancer	0.00398	0.00398	CcSEcCtD
Pindolol—Headache—Fludarabine—lymphatic system cancer	0.00398	0.00398	CcSEcCtD
Pindolol—Tachycardia—Carmustine—lymphatic system cancer	0.00397	0.00397	CcSEcCtD
Pindolol—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00394	0.00394	CcSEcCtD
Pindolol—Chest pain—Mitoxantrone—lymphatic system cancer	0.00394	0.00394	CcSEcCtD
Pindolol—Myalgia—Mitoxantrone—lymphatic system cancer	0.00394	0.00394	CcSEcCtD
Pindolol—Anxiety—Mitoxantrone—lymphatic system cancer	0.00393	0.00393	CcSEcCtD
Pindolol—Lethargy—Methotrexate—lymphatic system cancer	0.00391	0.00391	CcSEcCtD
Pindolol—Oedema—Vincristine—lymphatic system cancer	0.00388	0.00388	CcSEcCtD
Pindolol—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00384	0.00384	CcSEcCtD
Pindolol—Confusional state—Mitoxantrone—lymphatic system cancer	0.00381	0.00381	CcSEcCtD
Pindolol—Nervous system disorder—Vincristine—lymphatic system cancer	0.00381	0.00381	CcSEcCtD
Pindolol—Hypotension—Carmustine—lymphatic system cancer	0.0038	0.0038	CcSEcCtD
Pindolol—Oedema—Mitoxantrone—lymphatic system cancer	0.00378	0.00378	CcSEcCtD
Pindolol—Nausea—Fludarabine—lymphatic system cancer	0.00377	0.00377	CcSEcCtD
Pindolol—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00375	0.00375	CcSEcCtD
Pindolol—Shock—Mitoxantrone—lymphatic system cancer	0.00372	0.00372	CcSEcCtD
Pindolol—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.0037	0.0037	CcSEcCtD
Pindolol—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00369	0.00369	CcSEcCtD
Pindolol—Insomnia—Carmustine—lymphatic system cancer	0.00368	0.00368	CcSEcCtD
Pindolol—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00365	0.00365	CcSEcCtD
Pindolol—Paraesthesia—Carmustine—lymphatic system cancer	0.00365	0.00365	CcSEcCtD
Pindolol—Hypotension—Vincristine—lymphatic system cancer	0.00363	0.00363	CcSEcCtD
Pindolol—Dyspnoea—Carmustine—lymphatic system cancer	0.00362	0.00362	CcSEcCtD
Pindolol—Somnolence—Carmustine—lymphatic system cancer	0.00361	0.00361	CcSEcCtD
Pindolol—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00354	0.00354	CcSEcCtD
Pindolol—Hypotension—Mitoxantrone—lymphatic system cancer	0.00353	0.00353	CcSEcCtD
Pindolol—Insomnia—Vincristine—lymphatic system cancer	0.00351	0.00351	CcSEcCtD
Pindolol—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00351	0.00351	CcSEcCtD
Pindolol—Paraesthesia—Vincristine—lymphatic system cancer	0.00348	0.00348	CcSEcCtD
Pindolol—Pain—Carmustine—lymphatic system cancer	0.00348	0.00348	CcSEcCtD
Pindolol—Constipation—Carmustine—lymphatic system cancer	0.00348	0.00348	CcSEcCtD
Pindolol—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00344	0.00344	CcSEcCtD
Pindolol—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00339	0.00339	CcSEcCtD
Pindolol—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00337	0.00337	CcSEcCtD
Pindolol—Somnolence—Mitoxantrone—lymphatic system cancer	0.00336	0.00336	CcSEcCtD
Pindolol—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Pindolol—Feeling abnormal—Carmustine—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Pindolol—Fatigue—Vincristine—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Pindolol—Asthenia—Bleomycin—lymphatic system cancer	0.00334	0.00334	CcSEcCtD
Pindolol—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00333	0.00333	CcSEcCtD
Pindolol—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00332	0.00332	CcSEcCtD
Pindolol—Constipation—Vincristine—lymphatic system cancer	0.00332	0.00332	CcSEcCtD
Pindolol—Pain—Vincristine—lymphatic system cancer	0.00332	0.00332	CcSEcCtD
Pindolol—Pruritus—Bleomycin—lymphatic system cancer	0.00329	0.00329	CcSEcCtD
Pindolol—Fatigue—Mitoxantrone—lymphatic system cancer	0.00326	0.00326	CcSEcCtD
Pindolol—Constipation—Mitoxantrone—lymphatic system cancer	0.00323	0.00323	CcSEcCtD
Pindolol—Pain—Mitoxantrone—lymphatic system cancer	0.00323	0.00323	CcSEcCtD
Pindolol—Abdominal pain—Carmustine—lymphatic system cancer	0.00321	0.00321	CcSEcCtD
Pindolol—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00317	0.00317	CcSEcCtD
Pindolol—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00317	0.00317	CcSEcCtD
Pindolol—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00311	0.00311	CcSEcCtD
Pindolol—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00309	0.00309	CcSEcCtD
Pindolol—Abdominal pain—Vincristine—lymphatic system cancer	0.00307	0.00307	CcSEcCtD
Pindolol—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.00305	0.00305	CcSEcCtD
Pindolol—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00299	0.00299	CcSEcCtD
Pindolol—Vomiting—Bleomycin—lymphatic system cancer	0.00296	0.00296	CcSEcCtD
Pindolol—Drowsiness—Methotrexate—lymphatic system cancer	0.00295	0.00295	CcSEcCtD
Pindolol—Depression—Methotrexate—lymphatic system cancer	0.00294	0.00294	CcSEcCtD
Pindolol—Rash—Bleomycin—lymphatic system cancer	0.00294	0.00294	CcSEcCtD
Pindolol—Dermatitis—Bleomycin—lymphatic system cancer	0.00293	0.00293	CcSEcCtD
Pindolol—Asthenia—Carmustine—lymphatic system cancer	0.00292	0.00292	CcSEcCtD
Pindolol—Conjunctivitis—Methotrexate—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Pindolol—Sweating—Methotrexate—lymphatic system cancer	0.00283	0.00283	CcSEcCtD
Pindolol—Asthenia—Vincristine—lymphatic system cancer	0.00278	0.00278	CcSEcCtD
Pindolol—Diarrhoea—Carmustine—lymphatic system cancer	0.00278	0.00278	CcSEcCtD
Pindolol—Nausea—Bleomycin—lymphatic system cancer	0.00277	0.00277	CcSEcCtD
Pindolol—Asthenia—Mitoxantrone—lymphatic system cancer	0.00271	0.00271	CcSEcCtD
Pindolol—Dizziness—Carmustine—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Pindolol—Diarrhoea—Vincristine—lymphatic system cancer	0.00266	0.00266	CcSEcCtD
Pindolol—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Pindolol—Vomiting—Carmustine—lymphatic system cancer	0.00258	0.00258	CcSEcCtD
Pindolol—Dizziness—Vincristine—lymphatic system cancer	0.00257	0.00257	CcSEcCtD
Pindolol—Rash—Carmustine—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Pindolol—Dermatitis—Carmustine—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Pindolol—Visual impairment—Methotrexate—lymphatic system cancer	0.00255	0.00255	CcSEcCtD
Pindolol—Headache—Carmustine—lymphatic system cancer	0.00255	0.00255	CcSEcCtD
Pindolol—Tinnitus—Methotrexate—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Pindolol—Vomiting—Vincristine—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Pindolol—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Pindolol—Rash—Vincristine—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Pindolol—Dermatitis—Vincristine—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Pindolol—Headache—Vincristine—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Pindolol—Nausea—Carmustine—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Pindolol—Angiopathy—Methotrexate—lymphatic system cancer	0.0024	0.0024	CcSEcCtD
Pindolol—Vomiting—Mitoxantrone—lymphatic system cancer	0.0024	0.0024	CcSEcCtD
Pindolol—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Pindolol—Rash—Mitoxantrone—lymphatic system cancer	0.00238	0.00238	CcSEcCtD
Pindolol—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00238	0.00238	CcSEcCtD
Pindolol—Headache—Mitoxantrone—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Pindolol—Mental disorder—Methotrexate—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Pindolol—Nausea—Vincristine—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Pindolol—Nausea—Mitoxantrone—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Pindolol—Vertigo—Methotrexate—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Pindolol—Chest pain—Methotrexate—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Pindolol—Myalgia—Methotrexate—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Pindolol—Arthralgia—Methotrexate—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Pindolol—Confusional state—Methotrexate—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Pindolol—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Pindolol—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Pindolol—Hypotension—Methotrexate—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Pindolol—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Pindolol—Insomnia—Methotrexate—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Pindolol—Paraesthesia—Methotrexate—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Pindolol—Dyspnoea—Methotrexate—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Pindolol—Somnolence—Methotrexate—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Pindolol—Dyspepsia—Methotrexate—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Pindolol—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Pindolol—Fatigue—Methotrexate—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Pindolol—Pain—Methotrexate—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Pindolol—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Pindolol—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Pindolol—Abdominal pain—Methotrexate—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Pindolol—Asthenia—Methotrexate—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Pindolol—Pruritus—Methotrexate—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Pindolol—Diarrhoea—Methotrexate—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Pindolol—Dizziness—Methotrexate—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Pindolol—Vomiting—Methotrexate—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Pindolol—Rash—Methotrexate—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Pindolol—Dermatitis—Methotrexate—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Pindolol—Headache—Methotrexate—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Pindolol—Nausea—Methotrexate—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
